Clinical Trial Update: A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3) [Phase 2]

View source ↗

Summary

Phase 2 LCMC3 trial evaluating atezolizumab as neoadjuvant and adjuvant therapy in resectable non-small cell lung cancer has completed enrollment and posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-05-17